# A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

> **NCT05047601** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 2954 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PF-07321332
- **DRUG:** Placebo for PF-07321332
- **DRUG:** Placebo for Ritonavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT05047601
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2022-04-12
- **Final completion:** 2022-04-12
- **Target enrollment:** 2954 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047601, "A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05047601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*